Cancer Immunology In Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) has undergone remarkable therapeutic transformation with the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, accumulating evidence indicates that durable disease control depends not only on kinase inhibition, but also on effective anti-leukemic immunity. At diagnosis, both innate and adaptive immunity are profoundly dysregulated, characterized by an impaired natural killer cell function, T-cell exhaustion, the expansion of immunosuppressive cell populations, and the activation of immune checkpoint pathways. TKIs differentially remodel the immune microenvironment through off-target immunomodulatory effects, potentially contributing to treatment-free remission (TFR) in selected patients. Recent studies have further identified leukemic stem cell immune evasion mechanisms, bone marrow niche interactions, and host immunogenetic factors as factors associated with long-term disease control. This review summarizes current advances in cancer immunology in CML and discusses emerging immunological biomarkers and therapeutic strategies to achieve durable immune surveillance, TFR, and a functional cure.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2026-11-19
DOI
https://doi.org/10.2169/internalmedicine.8443-26
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cancer Immunology In Chronic Myeloid Leukemia

Hiroshi Ureshino
Internal Medicine
Chronic Myeloid Leukemia Treatments
article

Cancer Immunology In Chronic Myeloid Leukemia

Hiroshi Ureshino
article en

Abstract

Chronic myeloid leukemia (CML) has undergone remarkable therapeutic transformation with the introduction of BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, accumulating evidence indicates that durable disease control depends not only on kinase inhibition, but also on effective anti-leukemic immunity. At diagnosis, both innate and adaptive immunity are profoundly dysregulated, characterized by an impaired natural killer cell function, T-cell exhaustion, the expansion of immunosuppressive cell populations, and the activation of immune checkpoint pathways. TKIs differentially remodel the immune microenvironment through off-target immunomodulatory effects, potentially contributing to treatment-free remission (TFR) in selected patients. Recent studies have further identified leukemic stem cell immune evasion mechanisms, bone marrow niche interactions, and host immunogenetic factors as factors associated with long-term disease control. This review summarizes current advances in cancer immunology in CML and discusses emerging immunological biomarkers and therapeutic strategies to achieve durable immune surveillance, TFR, and a functional cure.

Internal Medicine
Saga University (JP)
Good health and well-being
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon